Renaturation assisting tag for purifying inclusion body protein and gene derivative product and application of renaturation assisting tag
By fusing the assisted regeneration tag P67 with the target protein and using its assisted regeneration function for dialysis and regeneration, the problem of failure of regeneration inclusion protein purification was solved, and efficient inclusion protein purification was achieved.
Patent Information
- Application Number
- CN202411867353.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-18
- Publication Date
- 2025-03-21
- Estimated Expiration
- 2044-12-18
AI Technical Summary
The prior art is difficult to effectively purify difficult-to-recover inclusion proteins, resulting in a failure of purification.
The regenerative tag P67 is used to express it in a fusion manner with the target protein, and the regenerative function of P67 is dialyzed and regenerative after denaturation, restoring the solubleness of inclusion proteins.
More than 68% of inclusion body proteins were achieved to restore solubleness, and the difficult-to-recover inclusion body proteins were successfully purified, avoiding recurrence failure.
Smart Images

Figure CN119662570A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of protein purification, and in particular relates to a refolding-aiding label for purifying inclusion body protein and a gene-derived product and application thereof. Background Art
[0002] Proteins are the main executors of life functions. The successful purification of biologically active proteins is crucial for subsequent protein function research and transformation applications. At present, many proteins have been successfully purified using gene recombination and prokaryotic expression purification systems. The biggest obstacle to the successful purification of proteins is the formation of inclusion bodies (IBs) by recombinant proteins. IB proteins are insoluble during the initial induction expression stage in the host bacteria. In the subsequent extraction and purification process, the addition of denaturants (urea and guanidine hydrochloride) makes the IB protein in a dissolved state. However, the denatured IB must undergo a slow renaturation step to remove the denaturant so that the IB protein can be correctly refolded and regain solubility and biological activity. Therefore, the renaturation process is particularly important for the successful purification of IB proteins. According to the difficulty of the renaturation process, IB proteins can be divided into two categories: renaturation-easy inclusion bodies (REIB) and renaturation-resistant inclusion bodies (RRIB). Among them, the formation of aggregates and precipitation by RRIB during the renaturation process is the main reason for the failure of inclusion body protein purification. Although some studies have found that adding small molecule compounds and changing the physical (pressure and pH) environment can improve the IB renaturation process, the results have been limited. Summary of the invention
[0003] In view of this, the object of the present invention is to provide a refolding-aiding tag, which can renature the denatured inclusion body protein, thereby achieving the purpose of purification.
[0004] The present invention provides a refolding aid tag P67, comprising at least one of the following: a PCC tag, a PC tag, an ACCA tag and a mutant of the PCC tag, PC tag or ACCA tag; the amino acid sequences of the PCC tag, PC tag and ACCA tag are shown in SEQ ID NO:1 to SEQ ID NO:3; the mutant of the PCC tag, PC tag or ACCA tag is characterized in that lysine at position 33 is mutated to glutamic acid or proline based on the amino acid sequence of the PCC tag, PC tag or ACCA tag.
[0005] The present invention provides a gene encoding the refolding aid tag P67, wherein the nucleotide sequence of the gene encoding is at least one of the following as shown in SEQ ID NO:4 to SEQ ID NO:8.
[0006] The present invention provides a prokaryotic protein expression tool plasmid, comprising a nucleic acid molecule expressing the renaturation-aiding tag P67 or the coding gene.
[0007] Preferably, the pET41a vector is used as the backbone vector, wherein the GST tag is replaced by the encoding gene.
[0008] Preferably, it also includes a HRV-3C protease recognition cleavage point or a TEV protease recognition site.
[0009] The present invention provides a prokaryotic recombinant vector for expressing a target protein, which uses the prokaryotic protein expression tool plasmid as a backbone vector and also includes a target protein gene;
[0010] The cloning site of the target protein gene is between the NcoI and XhoI multiple cloning sites or between the BamHI and XhoI multiple cloning sites.
[0011] The present invention provides a fusion protein obtained by fusion expression of the refolding aid tag P67 and a target protein.
[0012] The present invention provides a fusion gene, which is obtained by connecting the coding gene and the target gene in series.
[0013] The present invention provides the use of the refolding aid tag P67, the coding gene, the prokaryotic protein expression tool plasmid, the prokaryotic recombinant vector, the fusion protein or the fusion gene in inclusion body purification.
[0014] The present invention provides a method for purifying inclusion body protein, comprising the following steps:
[0015] Cloning the target protein gene into the prokaryotic protein expression tool plasmid to obtain a recombinant vector;
[0016] Transforming the recombinant vector into a competent prokaryotic expression system, culturing and inducing the target protein, and isolating the inclusion body protein;
[0017] Denaturing and dissolving the inclusion body protein to obtain denatured and dissolved inclusion body protein;
[0018] The denatured and dissolved inclusion body protein is dialyzed and renatured to obtain purified inclusion body protein.
[0019] The present invention provides a refolding aid tag P67, the amino acid sequence of which is at least one shown in SEQ ID NO:1 to SEQ ID NO:3, wherein the 33rd amino acid is lysine, glutamic acid or proline. The present invention fuses the refolding aid tag P67 with the target protein in a prokaryotic expression system, and the obtained fusion protein is an inclusion body protein carrying P67. The inclusion body protein carrying P67 is dissolved after denaturation, and then refolded in a refolding solution with a gradient concentration of urea. More than 68% of the inclusion body protein recovers solubility, achieving the purpose of purification, while the inclusion body protein not carrying P67 is partially or completely lost in the PBS dialysate, indicating that the refolding fails. It can be seen that the refolding aid tag P67 can effectively improve the refolding of inclusion bodies (difficult-refolding inclusion bodies), and lays a foundation for subsequent protein function research and application transformation. In addition, the refolding aid tag P67 is the currently disclosed refolding aid tag with the smallest molecular weight, which is conducive to the expression of fusion proteins without being limited by the carrier capacity. In addition, the refolding tag P67 is fused with the target protein for expression, and the resulting fusion protein is easily recognized by the biotin ligase of the host cell (eukaryote) or bacteria (prokaryote), and biotin is covalently linked to the lysine side chain in the MKM sequence in the refolding tag P67 to form a biotinylation modification; the biotinylated fusion protein can be purified under denaturing conditions using a biotin-avidin system with extremely high specificity and stability. It can be seen that the refolding tag P67 provided by the present invention can be widely used in the purification of inclusion body proteins. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The source and spatial structure analysis diagram of the P67 tag, where AE. The conserved domain shared by 5 eukaryotic carboxylases that can undergo biotinylation modification, and the structure in the red dotted circle is the spatial structure of the P67 tag; F. A schematic diagram of P67 consisting of 8 antiparallel β-sheets distributed on both sides of the middle MKM sequence; Note: Lysine K in MKM is the biotinylation site; The sequence with a gray background accompanied by 8 arrows forms a β-sheet; Red, green and blue letters represent the conserved sequences shared by 5, 4 and 3 carboxylases, respectively; ACCA: acetyl-CoA carboxylase A; ACCB: acetyl-CoA carboxylase B; PC: pyruvate carboxylase carboxylase); PCC: propionyl-CoA carboxylase; MCC: methylcrotonyl-CoA carboxylase;
[0021] Figure 2The diagrams are the structures of tool plasmids and control plasmids used to express fusion proteins with and without P67 tags, respectively, including A. The full sequence spectrum of tool plasmid pET-41a-P67-MCS; B. The schematic diagram of the structure of the tool plasmid used to express fusion proteins with P67 tags in T7 promoter and multiple cloning site; C. The schematic diagram of the structure of the vector constructed with control plasmid pET-41a-MCS to express fusion proteins without P67 tags; D. The schematic diagram of the sequence structure of HRV-3C protease cleavage site and MCS multiple cloning site;
[0022] Figure 3 The results of induced expression and dissolution of inclusion body protein Gal-12 observed by SDS-PAGE combined with Coomassie blue staining; A is the expression result of host bacteria culture fluid with P67 label induced by IPTG; B is the expression result of host bacteria culture fluid without P67 label induced by IPTG;
[0023] Figure 4 The dialysis renaturation results of the inclusion body protein Gal-12 detected by Coomassie blue staining, where A. the dialysis renaturation results of the Gal-12 protein with a P67 tag; B. the dialysis renaturation results of the Gal-12 protein without a P67 tag; C. the quantitative curve of the grayscale values of the two target protein bands in the above dialysis renaturation results, where the green curve is the renaturation curve of the Gal-12 protein with a P67 tag; the red curve is the renaturation curve of the Gal-12 protein without a P67 tag;
[0024] Figure 5 The results of induced expression and dissolution of inclusion body protein Int-2 detected by Coomassie blue staining, where A is the expression result of host bacteria culture fluid with P67 label induced by IPTG, and B is the expression result of host bacteria culture fluid without P67 label induced by IPTG;
[0025] Figure 6 The dialysis renaturation results of the inclusion body protein Int-2 observed by SDS-PAGE combined with Coomassie blue staining, where A. Dialysis renaturation results of Int-2 protein with P67 tag; B. Dialysis renaturation results of Int-2 protein without P67 tag; C. Quantitative curve of the grayscale values of the two target protein bands in the above dialysis renaturation results, the green curve is the renaturation curve of Int-2 protein with P67 tag; the red curve is the renaturation curve of Int-2 protein without P67 tag;
[0026] Figure 7 The results of induced expression and dissolution of inclusion body protein Gal-8S observed by SDS-PAGE combined with Coomassie blue staining; A is the expression result of host bacteria culture fluid with P67 label induced by IPTG; B is the expression result of host bacteria culture fluid without P67 label induced by IPTG;
[0027] Figure 8 .SDS-PAGE combined with Coomassie blue staining to observe the dialysis renaturation results of the inclusion body protein Gal-8S; A. Dialysis renaturation results of Gal-8S protein with P67 tag; B. Dialysis renaturation results of Gal-8S protein without P67 tag; C. Quantitative curve of the gray value of the two target protein bands in the above dialysis renaturation results, where the green curve is the renaturation curve of Gal-8S protein with P67 tag; the red curve is the renaturation curve of Gal-8S protein without P67 tag;
[0028] Fig. 9 The results of label removal of fusion inclusion body protein after refolding were observed by SDS-PAGE combined with Coomassie blue staining; A. The result of using HRV 3C protease to remove the extra label at the N-terminus of the fusion protein; B. The results of 3C protease digestion and purification of the three fusion proteins, the red arrows mark the tagged fusion proteins; the green arrows mark the target proteins after the label is removed; 3C protease MW: 22KD; N-terminal label MW: 13.4KD; E. After the supernatant protein Int-2 solution after 3C digestion flows through the nickel column (for removing the 3C protease carrying the His tag and the extra label at the N-terminus), the effluent is collected (Ni F lane), and the final target protein Int-2 is obtained; the red arrows mark the tagged fusion proteins; the green arrows mark the target proteins after the label is removed; 3C protease MW: 22KD; N-terminal label MW: 13.4KD;
[0029] Fig.10 This is the functional test result of the fusion inclusion body protein after successful refolding. The first column is the control column. No active protein is added. Chicken blood cells will agglutinate at the bottom and the solution will be clear. Columns 2-10 are test columns.
[0030] Fig.11 The results of purifying the refractory inclusion body protein using the P67 tag of other eukaryotic carboxylases; A. The results of the P67 tag of 5 eukaryotic carboxylases; B. The quantitative results of the electrophoresis, with the red arrow marking the tagged fusion protein;
[0031] Fig.12 Comparison results of purifying refractory inclusion body proteins using different tags; A. Purification results of inclusion body proteins with different tags; B. Quantitative results of electrophoresis; red arrows indicate tagged fusion proteins;
[0032] Fig.13The functional verification results after the mutation of "MKM" in the P67 tag into "MEM" and "MPM", including A. the primary structure of the P67 tag and its mutant tags; B. DNA sequencing results; E. purification results of the P67 tags with "MKM", "MEM" and "MPM"; F. quantitative results of the electrophoresis diagram;
[0033] Fig.14 The results are obtained by using a streptavidin column to purify the refractory inclusion body protein expressed by this system.
[0034] Fig.15 The figures are the results of purifying soluble proteins using streptavidin chromatography column and nickel column (Ni), respectively. DETAILED DESCRIPTION
[0035] The present invention provides a renaturation-promoting tag P67, comprising at least one of the following: a PCC tag, a PC tag, an ACCA tag and a mutant of the PCC tag, the PC tag or the ACCA tag. The amino acid sequence of the PCC tag is as shown in SEQ ID NO:1 (LRSPMPGVVVAVSVKPGDAVAEGQEICVIEAMKMQNSMTAGKTGTVKSVHCQAGDTVGEGDLL VELE); the amino acid sequence of the PC tag is as shown in SEQ ID NO:2 (IGAPMPGKVIDIKVVAGAKVAKGQPLCVLSAMKMETVVTSPMEGTVRKVHVTKDMTLEGDDLI LEIE); the amino acid sequence of the ACCA tag is as shown in SEQ ID NO:3 (MRSPSAGKLIQYIVEDGGHVFAGQCYAEIEVMKMVMTLTAVESGCIHYVKRPGAALDPGCVLA KMQL), and the mutant of the PCC tag, PC tag or ACCA tag is that lysine at position 33 is mutated to glutamic acid or proline based on the amino acid sequences of the PCC tag, PC tag and ACCA tag.
[0036] In the present invention, the refolding tag P67 is obtained by intercepting the conserved domain in the eukaryotic carboxylase sequence that can undergo biotinylation modification. P67 consists of 8 antiparallel β-sheets distributed on both sides of the middle MKM sequence. Lysine K in MKM is the biotinylation site. Figure 1The present invention screens the inclusion body protein solubility of eukaryotic carboxylases, including acetyl-CoA carboxylase A (ACCA), acetyl-CoA carboxylase B (ACCB), pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCC) and methylcrotonyl-CoA carboxylase (MCC). The results show that the label P67 derived from ACCA, PC and PCC has similar renaturation function, while the label P67 derived from ACCB (LRSPSAGKLTQYTVEDGGHVEAGSSYAEMEVMKMI
[0037] MTLNVQERGRVKYIKRPGAVLEAGCVVARLEL, SEQ ID NO: 13) and MCC-derived tag P67 (PLAPMTGTIEKVFVKAGDKVKAGDSLMVMIAMKMEHTIKSPK
[0038] DGTVKKVFYREGAQANRHTPLVEFE, SEQ ID NO: 14) does not have good co-renaturation function.
[0039] In the present invention, the eukaryotic carboxylase sequence contains a MKM sequence, which is easily recognized by the biotin ligase of the host cell (eukaryote) or bacteria (prokaryote), and the biotin is covalently linked to the lysine side chain in the MKM sequence in the refolding tag P67 to form a biotinylation modification; the biotinylated fusion protein can be purified under denaturing conditions using a biotin-avidin system with extremely high specificity and stability. In order to verify whether the biotin modification of lysine (K) in the MKM sequence will affect the solubility function of the refolding tag P67, the present invention mutates the "MKM" of the tag P67 into "MEM" and "MPM", and the resulting tag P67 still has a good refolding function, which indicates that the above amino acid mutation will not affect the solubility effect of the tag P67.
[0040] The present invention provides a gene encoding the renaturation-promoting tag P67.
[0041] In the present invention, the gene encoding of P67 of ACCA is:
[0042] atgcgctcaccttctgctgggaagttaatccagtacattgtagaagatggaggtcatgtgtttgccggccagtgctatgctgagattgaggtaatgaagatggt aatgaccttaacagctgtggagtctggctgtatccattacgtcaagcgacctggagcagctcttgaccctggctgtgtactagccaaaatgcaactg(SEQ ID NO:4);
[0043] Gene encoding P67 of PC:
[0044] atcggggcgcccatgcctgggaaggtgatagacatcaaagtggtggcaggggccaaggtggccaagggccagcccctgtgtgtgctcagtgcc atgaagatggagactgtggtgacctcacccatggagggtactgtccgcaaggttcatgtgaccaaggacatgacactggaaggtgacgacctcatcctgg agatcgag(SEQ ID NO:5);
[0045] Gene encoding P67 of PCC:
[0046] ctgcgttccccgatgcccggagtggtggtggccgtctctgtcaagcctggagacgcggtagcagaaggtcaagaaatttgtgtgattgaagccatg aaaatgcagaatagtatgacagctgggaaaactggcacggtgaaatctgtgcactgtcaagctggagacacagttggagaaggggatctgctcgtggagc tggaa(SEQ ID NO:6);
[0047] Encoding gene of P67 MEM:
[0048] Ctgcgttccccgatgcccggagtggtggtggccgtctctgtcaagcctggagacgcggtagcagaaggtcaagaaatttgtgtgattgaagccatg gaaatgcagaatagtatgacagctgggaaaactggcacggtgaaatctgtgcactgtcaagctggagacacagttggagaaggggatctgctcgtggagc tggaa (SEQ ID NO: 7), wherein the underline indicates the mutation site;
[0049] P67 MPM encoding gene:
[0050] Ctgcgttccccgatgcccggagtggtggtggccgtctctgtcaagcctggagacgcggtagcagaaggtcaagaaatttgtgtgattgaagccatg cct atgcagaatagtatgacagctgggaaaactggcacggtgaaatctgtgcactgtcaagctggagacacagttggagaaggggatctgctcgtggagct ggaa (SEQ ID NO: 8), wherein the underline indicates the mutation site;
[0051] The gene encoding P67 of ACCB:
[0052] ctgagatccccctcggctgggaagctgacacagtacacagtggaggatgggggccacgttgaggctgggagcagctacgctgagatggaggtg atgaagatgatcatgaccctgaacgttcaggaaagaggccgggtgaagtacatcaagcgtccaggtgccgtgctggaagcaggctgcgtggtggccagg ctggagctc(SEQ ID NO:9);
[0053] The gene encoding P67 of MCC:
[0054] cccttagctcctatgactggaaccattgaaaaggtgtttgtcaaagctggagacaaagtgaaagcggggagattccctcatggttatgatcgccatgaa gatggagcataccataaagtctccaaaggatggcacagtaaagaaagtgttctacagagaaggtgctcaggccaacagacacactcctttagtcgagtttga g (SEQ ID NO: 10).
[0055] In the present embodiment, a control tag-assisted remodeling experiment was also carried out, wherein the amino acid sequence of the Avi tag is
[0056] GLNDIFEAQKIEWHE (SEQ ID NO: 11). The amino acid sequence of the Trx tag is
[0057] SDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIA DEYQGKLTVAKLNIDQNPGTAPKYGIRGIPTLLLLFKNGEVAATKVGALSKGQLKEFLDANLA (SEQ ID NO: 12).
[0058] The present invention provides a prokaryotic protein expression tool plasmid, comprising the coding gene of the renaturation-aiding tag P67 or the coding gene.
[0059] In the present invention, the coding gene is preferably obtained by sequence optimization according to the codon preference of Escherichia coli.
[0060] In the present invention, the prokaryotic protein expression tool plasmid is preferably a pET41a vector as a backbone vector, wherein the GST tag is replaced by the coding gene. The cloning site of the coding gene is preferably between the NdeI and SpeI restriction sites. The prokaryotic protein expression tool plasmid construction method preferably connects one end of the coding gene of the renaturing tag P67 to the Nde I restriction endonuclease sticky end (SEQ ID NO: 15, TATGTCGGATGGTTCAA), and the other end is connected to the SpeI restriction endonuclease sticky end (SEQ ID NO: 16, CTAGTTGAACCATCCGACA), and the obtained coding gene and backbone vector of the renaturing tag P67 with restriction sites are digested by Nde I and SpeI restriction endonucleases, respectively, and the obtained products are connected to obtain the prokaryotic protein expression tool plasmid, which is recorded as pET41a-P67-MCS.
[0061] In the present invention, the prokaryotic protein expression tool plasmid preferably also includes a HRV-3C protease recognition cleavage point or a TEV protease recognition site. The HRV-3C protease recognition cleavage point is LEVLFQ↑GP (SEQ ID NO: 17), and the TEV protease recognition site is ENLYFQ↑S (SEQ ID NO: 18), wherein ↑ is a protease cleavage site. The pET41a vector originally carried thrombin and enterokinase recognition sites, but due to the low specificity of thrombin (Thrombin, recognition site is LVPR↑GS, SEQ ID NO: 19) and enterokinase (Enterokinase, recognition site is DDDD↑K, SEQ ID NO: 20), they recognize 6 and 5 consecutive amino acid conservative sequences respectively, and when the enzyme is used to remove the tag in the later stage, it is easy to cause non-specific cleavage of the target protein. The present invention replaces the HRV-3C protease recognition cleavage point or the TEV protease recognition site to improve the effect of specific enzyme cleavage, which is beneficial to avoid non-specific cleavage of the target protein. The whole gene synthesis business of the above-mentioned vector modification was entrusted to Sangon Biotech (Shanghai) Co., Ltd.
[0062] The invention provides a prokaryotic recombinant vector for expressing a target protein, which uses the prokaryotic protein expression tool plasmid as a backbone vector and also includes a target protein gene; the cloning site of the target protein gene is between the NcoI and XhoI multiple cloning sites or between the BamHI and XhoI multiple cloning sites.
[0063] In the present invention, the method for constructing the prokaryotic recombinant vector preferably comprises the steps of double-digesting the target protein gene with BamHI and XhoI multiple cloning sites at both ends and the prokaryotic protein expression tool plasmid with BamHI and XhoI restriction endonucleases respectively, and connecting the digestion products to obtain the prokaryotic recombinant vector.
[0064] In the present invention, the target protein gene includes at least one of the following proteins or truncated genes: Int-2 protein (SEQ ID NO: 21), Gal-8S protein (SEQ ID NO: 22) and Gal-12 protein (SEQ ID NO: 23). The amino acid sequence of the truncated Gal-12 protein is shown in SEQ ID NO: 24.
[0065] In one embodiment of the present invention, the inclusion body protein obtained by recombinant expression in Escherichia coli using a prokaryotic recombinant vector was successfully renatured under the action of the renaturation-aiding tag P67, while the inclusion body protein without the renaturation-aiding tag P67 was completely lost in the PBS dialysate, indicating renaturation failure.
[0066] In one embodiment of the present invention, in order to further verify that the successful renaturation of the target protein is affected by the renaturation-aiding tag P67, the present invention uses the 3C protease cleavage site to remove the tag sequence of the target protein, and the de-tagged target protein is partially or completely lost during the renaturation process, which indicates that the P67 tag is essential for maintaining the soluble state of the target protein.
[0067] In another embodiment of the present invention, in order to verify the activity of the target protein that has been successfully renatured, three target protein activity detection experiments were carried out, and the results showed that P67-Int-2 and P67-Gal-8S have biological activity and can cause chicken blood agglutination, and P67-Gal-12 does not show biological activity. The present invention recombinantly expresses the P67-Gal-12 truncation (N-terminal sequence of Gal-12) to obtain inclusion body protein, and then successfully purifies the target protein with biological activity through denaturation and renaturation, which indicates that the C-terminal structure of Gal-12 may hinder the function of the protein.
[0068] The present invention provides a fusion protein obtained by fusion expression of the refolding aid tag P67 and a target protein.
[0069] The present invention provides a fusion gene, which is obtained by connecting the coding gene and the target gene in series.
[0070] The present invention provides the use of the refolding aid tag P67, the coding gene, the prokaryotic protein expression tool plasmid, the prokaryotic recombinant vector, the fusion protein or the fusion gene in inclusion body purification.
[0071] The present invention provides a method for purifying inclusion body protein, comprising the following steps:
[0072] Cloning the target protein gene into the prokaryotic protein expression tool plasmid to obtain a recombinant vector;
[0073] Transforming the recombinant vector into a competent prokaryotic expression system, culturing and inducing the target protein, and separating the inclusion body protein;
[0074] Denaturing and dissolving the inclusion body protein to obtain denatured and dissolved inclusion body protein;
[0075] The denatured and dissolved inclusion body protein is dialyzed and renatured to obtain purified inclusion body protein.
[0076] The present invention clones the target protein gene into the prokaryotic protein expression tool plasmid to obtain a recombinant vector.
[0077] In the present invention, the cloning method is the same as the method for constructing a prokaryotic recombinant vector for expressing a target protein in the above technical solution, and will not be described in detail here.
[0078] After obtaining the recombinant vector, the present invention transforms the recombinant vector into a prokaryotic expression system competent state, and isolates the inclusion body protein through culture and induction of the target protein.
[0079] The present invention has no special restrictions on the method of transformation, and a transformation scheme well known in the art is adopted. In an embodiment of the present invention, the transformation is performed by heat shock method. The prokaryotic expression system is preferably Escherichia coli. The competent Escherichia coli can be BL21 (DE3) PLysS (Weidi Biotechnology, #EC1003). The culture is preferably inoculated in LB medium with the strain and cultured at 37°C and 225rpm. The culture is preferably expanded to the logarithmic growth phase. The conditions of the amplification culture are the same as above and are not repeated here. The induction agent is preferably IPTG. The induction concentration of IPTG is preferably 1mM. The induction time is preferably 3 to 5h, and can be 4h.
[0080] After obtaining the inclusion body protein, the present invention denatures and dissolves the inclusion body protein to obtain denatured and dissolved inclusion body protein.
[0081] In the present invention, the denaturing and dissolving method preferably places the inclusion body protein in buffer A, buffer B, and buffer C in sequence to separate the precipitate, then mixes and dissolves the precipitate with buffer D, collects the supernatant, and obtains the denatured and dissolved inclusion body protein. The buffer A is preferably an aqueous solution comprising the following contents: 50mM Tris-HCl (pH 8.5), 1mM EDTA, 100mM NaCl, and 1% Triton X-100 by volume. The buffer B is preferably an aqueous solution comprising the following contents: 50mM Tris-HCl (pH 8.5), 1mM EDTA, 100mM NaCl, 1% Triton X-100 by volume, and 2M urea. Buffer C is preferably an aqueous solution comprising the following contents: 50mM Tris-HCl (pH 8.5), 1mM EDTA, 100mM NaCl, 1% Triton X-100 by volume, and 2M guanidine hydrochloride. The buffer D is preferably an aqueous solution comprising the following contents: 50 mM Tris-HCl (pH 8.5), 1 mM EDTA, 100 mM NaCl, 10 mM DTT, 2 mM sodium deoxycholate and 8 M urea.
[0082] After obtaining the denatured and dissolved inclusion body protein, the present invention performs dialysis renaturation on the denatured and dissolved inclusion body protein to obtain purified inclusion body protein.
[0083] In the present invention, the dialysis refolding solution is an aqueous solution containing gradient concentration of urea, preferably including the following components: 50mM Tris-HCl (pH 8.5), 100mM NaCl, gradient concentration of urea, 1% glycine, 5% glycerol, 0.2% PEG (Mr3550), 1mM oxidized glutathione and 1mM reduced glutathione. The gradient concentrations of urea are preferably 6M, 4M, 2M and 1M, respectively. The denatured and dissolved inclusion body protein is dialyzed in descending order of urea concentration. The dialysis time is 6h, and the dialysis temperature is preferably 4°C. The molecular weight cutoff of the dialysis bag for dialysis is selected according to the size of the target protein.
[0084] In the present invention, after the dialysis renaturation, it is preferred to further include protein content determination and activity determination. The protein content determination method is preferably detected by Coomassie blue staining. The activity determination is preferably determined by chicken blood agglutination test.
[0085] The following is a detailed description of a refolding aid tag for purifying inclusion body proteins provided by the present invention, its gene-derived products and applications, in conjunction with the examples. However, they should not be construed as limiting the scope of protection of the present invention.
[0086] Example 1
[0087] A method for constructing a prokaryotic protein expression tool plasmid
[0088] The GST tag on the pET41a vector (Novagen, #71071) was replaced with a P67 tag (LRSPMPGVVVAVSVKPGDAVAEGQEICVIEAMKMQNSMTAGKTGTVKSVHCQAGDTVGEGDLL VELE, SEQ ID NO: 1), and the enterokinase site was transformed into an HRV-3C protease cleavage site (LEVLFQ↑GP, SEQ ID NO: 17, ↑ indicates the enzyme cleavage position) to obtain the prokaryotic protein expression tool plasmid pET-41a-P67-MCS (SEQ ID NO: 31). The whole gene synthesis business of the above-mentioned vector transformation was commissioned to be completed by Sangon Biotech (Shanghai) Co., Ltd.
[0089] The multiple cloning site MCS on the tool plasmid pET-41a-P67-MCS is used to insert the target protein coding sequence to form an expression vector; the HRV-3C protease cleavage site upstream of MCS is used to remove the redundant N-terminal tag ( Figure 2 (middle AB).
[0090] In this example, a control plasmid (pET-41a-MCS, SEQ ID NO: 32) was also constructed. The construction method was different from that of the tool plasmid pET-41a-P67-MCS in that the control plasmid did not contain the cloned P67 tag sequence ( Figure 2 The whole gene synthesis of the control plasmid was commissioned to Sangon Biotech (Shanghai) Co., Ltd.
[0091] Example 2
[0092] In order to verify the function of the P67 tag, six vectors for expressing three human RRIBs were constructed in this example, including three expression vectors with P67 tags and three control vectors without P67 tags. Specific information of the target protein and vector is shown in Table 1.
[0093] Table 1. Prokaryotic expression recombinant vector and control plasmid
[0094]
[0095] The construction method includes the following steps:
[0096] 1. Primer sequences
[0097] The primers used to amplify the Intelectin-2 gene are as follows:
[0098] Int-2 BamHI FP: AATCGGGGATCCACCTGTGCGTTTAGCTTTA (SEQ ID NO: 25);
[0099] Int-2 XhoI RP: GTGGTGCTCGAGTTAACGGTAAAACAGCAGAACT (SEQ ID NO: 26);
[0100] The primers used to amplify the Galectin-12 gene are as follows:
[0101] Gal-12 NcoI FP:CCCAGTCCCATGGAGTCAACCGTCTGGCGGTC (SEQ ID NO: 27);
[0102] Gal-12 EcoRI RP: GCCTGTACAGAATTCTTAGCTATGAACGCAATACAGC (SEQ ID NO: 28);
[0103] The primers used to amplify the Galectin-8S gene are as follows:
[0104] Gal-8S BamHI FP: AATCGGGGATCCATGATGCTGAGCCTGAAC (SEQ ID NO: 29);
[0105] Gal-8S XhoI RP: GTGGTGCTCGAGTTACCAACTACGAACTTCCAG (SEQ ID NO: 30).
[0106] Using the ORF of the target protein encoding gene as a template, PCR amplification was performed using the above primers containing restriction sites to obtain the Int-2, Gal-12 and Gal-8S gene sequences. The PCR amplification system was 50 μL (including 2×PCR buffer 25 μL, 1 μL of 10 μM upstream and downstream primers, 1 μL of template, and water was added to make up to 50 μL). The PCR amplification program was 95°C for 4 min, (95°C for 10 s, 65°C for 30 s, 72°C for 1 min) 35 cycles, and 72°C for 5 min to obtain the PCR product.
[0107] The PCR product and the tool plasmid pET-41a-P67-MCS or the control plasmid pET-41a-MCS were subjected to double digestion reaction under the action of BamHI (NEB, #R3136) and XhoI (NEB, #R0146) restriction endonucleases, the reaction system was 50 μL (including 5 μL of 10× digestion buffer, 1 μL of each restriction endonuclease, 10 μg of template plasmid, and water was added to make up to 50 μL), and the reaction procedure was digestion at 37°C for 1 hour to obtain PCR products with sticky ends and linear tool plasmid pET-41a-P67-MCS or control plasmid respectively; 10 μL of ligation reaction system (NEB, #M0202; including 1 μL of 10X digestion buffer, 1 μL of T4 DNA ligase, 1 μg of template plasmid, 0.5 μg of PCR enzyme digestion product, and water was added to make up to 10 μL), and ligation was performed at room temperature for 2 hours to obtain a ligation product.
[0108] The ligation product was transformed into the competent E. coli BL21 (DE3) PLysS (Weidi Biotechnology, #EC1003) by heat shock method, cultured overnight at 37°C, and identified by colony PCR. Specifically, the PCR reaction system was configured with the above primers, and the reaction program was 95°C for 4 min, (95°C for 10 s, 65°C for 30 s, 72°C for 1 min) 35 cycles, and 72°C for 5 min. The amplified product was detected by agarose gel electrophoresis, and the expected size of the electrophoresis band was obtained, indicating that the transformation was successful.
[0109] Example 3
[0110] Recombinant expression and purification of target protein
[0111] 1. Recombinant expression method of target protein
[0112] The three recombinant bacteria successfully transformed with the target genes in Example 2 were selected and inoculated into 2 ml LB liquid culture medium containing corresponding antibiotics for activation and culture overnight. The temperature of the constant temperature shaker was set at 37° C. and the rotation speed was 225 rpm.
[0113] Add 0.6 ml of overnight cultured host bacteria to each flask containing 50 ml LB medium (without antibiotics) (capacity is 5 times the volume of culture medium) and culture at 37°C in a constant temperature shaker until OD 600 0.6, about 3h.
[0114] Add IPTG to the culture flask to make the final concentration of IPTG reach 1 mM, and culture it in a 37°C constant temperature shaker for 4 h to induce protein expression.
[0115] 2. Lysis of host bacteria and denaturation and dissolution of inclusion body proteins
[0116] The induced expression bacterial solution was centrifuged at 5000 g for 10 min, the supernatant was discarded, and the bacterial pellet was retained.
[0117] Resuspend the bacterial pellet with buffer A (resuspend the centrifuged bacterial cells with 5 ml buffer A for every 100 ml LB culture), disrupt the bacterial suspension with ultrasound (power 45%, work 2s, pause 2s, disruption 10min), and then centrifuge at 10,000g for 10min; wash the inclusion body pellet collected by centrifugation with PBS buffer (repeatedly aspirate with a syringe) once, centrifuge, discard the supernatant, and collect the pellet.
[0118] The precipitate was resuspended in buffer B (by repeatedly aspirating the precipitate with a syringe) and then ultrasonically disrupted for 5 minutes under the same conditions; after ultrasonication, the precipitate was centrifuged at 10,000 g for 10 minutes, the supernatant was discarded, and the inclusion body precipitate was collected.
[0119] The inclusion body precipitate was washed by ultrasonication with buffer C for 3 min (the precipitate was repeatedly aspirated with a syringe); and the precipitate was collected by centrifugation at 10,000 g for 10 min.
[0120] Dissolve the inclusion bodies with buffer D (repeatedly draw out the precipitate with a syringe) to allow the inclusion bodies to dissolve slowly. After standing at room temperature for 30 minutes, centrifuge at 10,000 g for 10 minutes. The supernatant is the denatured and dissolved inclusion body protein.
[0121] The concentration of dissolved inclusion body protein was measured using a BCA protein quantification kit; the protein concentration was adjusted to 0.1-1.0 mg / ml.
[0122] 3. Dialysis refolding of inclusion body proteins
[0123] The adjusted protein solution was placed in a dialysis bag, placed in a beaker containing refolding buffer (containing 6 M urea) (the capacity was at least 500 times the dialysis volume), and dialyzed slowly at 4°C for 6 h.
[0124] The dialysis bag was transferred to the refolding buffer (containing 4 M urea) and dialyzed slowly at 4°C for 6 h.
[0125] The dialysis bag was transferred to the refolding buffer (containing 2 M urea) and dialyzed slowly at 4°C for 6 h.
[0126] The dialysis bag was transferred to the refolding buffer (containing 1 M urea) and dialyzed slowly at 4°C for 6 h.
[0127] Finally, the dialysis bag was placed in PBS and dialyzed slowly at 4°C overnight.
[0128] SDS-PAGE combined with Coomassie blue staining was used to detect protein purity.
[0129] In the above experimental process, the solutions required for the induction expression, denaturation dissolution and dialysis refolding of inclusion body protein are:
[0130] PBS: 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4;
[0131] Buffer A: 50 mM Tris-HCl (pH 8.5), 1 mM EDTA, 100 mM NaCl, 1% Triton X-100;
[0132] Buffer B: 50 mM Tris-HCl (pH 8.5), 1 mM EDTA, 100 mM NaCl, 1% Triton X-100, 2 M urea;
[0133] Buffer C: 50 mM Tris-HCl (pH 8.5), 1 mM EDTA, 100 mM NaCl, 1% Triton X-100, 2 M guanidine hydrochloride;
[0134] Buffer D: 50 mM Tris-HCl (pH 8.5), 1 mM EDTA, 100 mM NaCl, 10 mM DTT, 2 mM sodium deoxycholate, 8 M urea;
[0135] Renaturation buffer: 50 mM Tris-HCl (pH 8.5), 100 mM NaCl, containing 6 M, 4 M, 2 M, 1 M urea, 1% glycine, 5% glycerol, 0.2% PEG (Mr3550), 1 mM oxidized glutathione and 1 mM reduced glutathione respectively.
[0136] result
[0137] In this example, purification experiments of RRIB of three target proteins were carried out. The results showed that Gal-12, Int-2 and Gal-8S proteins were all expressed in the form of inclusion bodies. Figure 3 As shown: The target protein Gal-12 only appears in the precipitate after the bacteria are lysed using buffer A, with a P67 tag ( Figure 3 A) and without P67 tag ( Figure 3 The Gal-12 fusion protein in (B) can be completely dissolved in Buffer D containing 8M urea denaturant and appears in the supernatant. During the dialysis process, as the urea concentration gradually decreased from 8M to a PBS solution completely free of urea, 76% of the P67-tagged Gal-12 protein regained solubility, indicating successful refolding ( Figure 4 The Gal-12 protein without P67 tag was completely lost in the PBS dialyzate, indicating that the renaturation failed ( Figure 4 (B).
[0138] Figure 5 The results showed that the Int-2 protein was expressed in the form of inclusion bodies. The Int-2 protein only appeared in the precipitate after the bacteria were lysed using buffer A, with a P67 tag ( Figure 5 A) and without P67 tag ( Figure 5 Int-2 fusion protein in B) can be completely dissolved in Buffer D containing 8M urea denaturant and appears in the supernatant. During the dialysis process, as the concentration of urea gradually decreased from 8M to a PBS solution completely free of urea, 68% of the Int-2 protein with the P67 tag regained solubility, indicating successful refolding ( Figure 6 Int-2 protein without P67 tag was completely lost in PBS dialyzate, indicating that renaturation failed ( Figure 6 (B).
[0139] Figure 7 The results showed that the Gal-8S protein was also expressed in the form of inclusion bodies. The Gal-8S protein only appeared in the precipitate after the bacteria were lysed using buffer A, with a P67 tag ( Figure 7 A) and without P67 tag ( Figure 7 The Gal-8S fusion protein in (B) can be completely dissolved in Buffer D containing 8M urea and appears in the supernatant. During the dialysis process, as the concentration of urea gradually decreased from 8M to a PBS solution completely free of urea, 91% of the Gal-8S protein with the P67 tag regained solubility, indicating successful refolding ( Figure 8 Only 26% of the Gal-8S protein without P67 tag regained solubility ( Figure 8 (B).
[0140] Example 4
[0141] Reverse verification of the effect of P67 tag on target protein renaturation
[0142] according to Figure 2 Figure C shows the construction of a recombinant vector expressing three target proteins (Gal-12, Int-2 and Gal-8S). For specific steps, see the recombinant vector construction method in Example 2.
[0143] According to the purification method of Example 3, three fusion proteins were successfully refolded and then the P67 tags were removed using 3C protease (Takara, #7360). The specific reaction conditions were 500 μL (including 50 μL of 10X digestion buffer, 10 μL of 3C protease, 100 μg of protein to be digested, and water was added to make up to 500 μL), and the reaction procedure was digestion at 4°C for 16 hours.
[0144] After the enzyme cleavage reaction, the de-tagged protein was subjected to a nickel ion chromatography column (Biyuntian, #P2233) to remove the 3C protease and P67 tags. The specific steps were to pass the 500 μL protein solution after the above digestion through a 100 μL nickel column at room temperature, and then collect the effluent to obtain three purified de-tagged target proteins. The results of electrophoresis detection of the sample showed that the inclusion body protein that was successfully renatured was a fusion protein carrying the P67 tag, but when the 3C protease cleavage site was used to remove the N-terminal redundant tag, the purified de-tagged target protein Gal-12 ( Fig. 9 B) was completely lost in the supernatant; while Gal-8S ( Fig. 9 C) and Int-2( Fig. 9 In D), some residues remain in the supernatant, but most of the target proteins form precipitates. This indicates that the P67 tag is essential for maintaining the soluble state of the target protein, and some inclusion body proteins must carry the P67 tag to remain soluble.
[0145] The supernatant protein Int-2 solution after 3C digestion was passed through a nickel column (for removing the 3C protease carrying the His tag and the N-terminal redundant tag P67), and the effluent was collected. The effluent was subjected to electrophoresis detection, and the final target protein with a purity of about 90% appeared in the Ni F lane ( Fig. 9 This indicates that the system can be used to successfully renature the difficult-to-renature inclusion body protein and remove the tag, ultimately obtaining the target protein.
[0146] Example 5
[0147] Use hemagglutination assay to detect the activity of successfully renatured inclusion body proteins
[0148] The first column of the 96-well V-shaped plate was set as the negative control, and the second to tenth columns were used as the experimental group. 75 μL of buffer containing 150 mM NaCl and 10 mM Tris (pH 7.5) was added to wells 1 to 10, 100 μg / mL of the protein to be tested was added to the rightmost well, 75 μL of liquid was taken out and mixed with the liquid in the previous well, and gradually diluted to the second well from right to left at a ratio of 1:1, and then 75 μL of liquid was discarded; 25 μL of 2% (V / V) chicken erythrocyte suspension was added to each well and mixed; it was left to stand on ice for 1 hour, and the aggregation of chicken erythrocytes was observed by taking pictures, and the minimum concentration required for the target protein to induce complete aggregation of erythrocytes was recorded.
[0149] The results showed that P67-Int-2 and P67-Gal-8S had biological activity and could induce chicken blood agglutination ( Fig.10 ). P67-Gal-12 showed no biological activity, and it is speculated that the C-terminal structure may hinder the protein from functioning.
[0150] The C-terminal structure of Gal-12 was removed, and the coding gene sequence (SEQ ID NO: 33) expressing only the N-terminal polypeptide of Gal-12 (SEQ ID NO: 24) was cloned into the tool plasmid. The specific method is shown in Example 3. The Gal-12 truncation with P67 tag (P67-Gal-12 N-ter) was isolated according to the recombinant expression method and purification method of Example 3 and the activity was tested.
[0151] The results showed that the protein truncation also belonged to RRIB and could be successfully purified using this system and had biological activity ( Fig.10 ).
[0152] Example 6
[0153] Compare the purification of the difficult-to-refold inclusion body protein Int-2 using the P67 tag of other carboxylases.
[0154] In this example, the P67 sequences of carboxylases (ACCA, ACCB, MCC, PC) from different eukaryotic sources were used to construct tool plasmids according to the method of Example 1, and the obtained tool plasmids were cloned into the Int-2 gene to obtain a prokaryotic expression recombinant vector. The recombinant expression protein and purification were performed according to the method of Example 3.
[0155] The results showed that the P67 tags from ACCA and PC had similar renaturation-promoting functions as the P67 tags from PCC; however, the P67 tags from ACCB and MCC had no renaturation-promoting function, and all Int-2 was lost in the PBS dialysate phase after dialysis ( Fig.11 ).
[0156] Comparative Example 1
[0157] The P67 tag, Avi tag, Trx tag and Int-2 protein were fused and expressed in E. coli, and the recombinant protein was purified according to the method of Example 3.
[0158] Results Fig.12 and Table 2.
[0159] Table 2 Results of purification of difficult-to-refold inclusion body proteins using different tags
[0160] The results showed that the Trx tag had a certain renaturation-promoting function, but the effect was lower than that of the P67 tag; similarly, the Avi tag had no renaturation-promoting function, and all of the Int-2 after dialysis was lost in the PBS dialysate stage.
[0161] Example 7
[0162] In order to avoid the possible impact of biotinylation modification on the P67 tag (occurring on the lysine side chain in MKM) on the use of the target protein, this example verifies the mutation of lysine in "MKM" in the P67 tag to proline and glutamate, and the purification function of the mutated tag P67 is detected according to the method of Example 3.
[0163] The results showed that mutation of P67 MKM to MEM and MPM did not affect the refolding function of the tag ( Fig.13 ).
[0164] Example 8
[0165] The experiments of purifying the P67-tagged inclusion bodies (purified under denaturing conditions) and soluble proteins (purified under non-denaturing conditions) using streptavidin chromatography system
[0166] This example first determined that the target protein carrying the P67 tag in this system can be biotinylated in the host bacteria. The host bacteria carrying the recombinant plasmid pET-41a-P67-Gal-12 N-ter were induced to express by IPTG for 4 hours, and the bacterial solution was collected, and the whole cell lysate was analyzed by SDS-PAGE combined with Coomassie blue staining. At the same time, the bacterial solution after IPTG induction was centrifuged, and Buffer D containing 8M urea was directly added to lyse the cells (2mL Buffer D was added to every 50 mL of culture medium for bacteria). The lysate was passed through a streptavidin chromatography column (200μL column volume), and the chromatography column was washed with 10 times the column volume of Buffer D. 20μL of stationary phase beads were aspirated, and the bound proteins on the beads were detected by electrophoresis. It can be seen that the target protein is bound to the chromatography column, as shown by the red arrow ( Fig.14The remaining beads were taken out and placed in a dialysis bag for dialysis (according to the method in Example 3); HRV 3C protease was added to the dialysis column after dialysis for in-column digestion (digestion at 4°C for 16 hours); finally, 3 column volumes of PBS were used as eluent to elute the column. The eluate was subjected to electrophoresis and staining detection, and it can be seen that the target protein (green arrow) that has been successfully renatured and has had its label removed appears in the eluate ( Fig.14 The results show that the refractory inclusion body protein induced by this system can be purified by streptavidin chromatography under deformation conditions. This example also uses IRDye 680 to label streptavidin for Western Blot detection of the above samples. It can be seen that there is a strong streptavidin binding signal at the location of the fusion protein ( Fig.14 (B) This demonstrates that the P67 tag of the present invention can be modified with biotin.
[0167] The coding sequence of the soluble protein Galectin-8 was inserted between the BamHI and XhoI sites according to the cloning method in Example 2 to form a recombinant vector pET-41a-P67-Gal-8. The recombinant vector pET-41a-P67-Gal-8 was transformed into a competent host bacteria, and IPTG was induced to express after cultivation, and the recombinant protein was isolated and detected. It can be seen that the blue-stained band of the target protein appeared at the expected molecular weight position ( Fig.15 ), the red arrow indicates the Gal-8 fusion protein with a P67 tag. According to the operating steps in Example 3, the host bacteria were lysed with Buffer A and centrifuged, and the obtained supernatant and precipitate were subjected to SDS-PAGE and Coomassie blue staining detection. It can be seen that the target protein appears in the supernatant (Supernatant, Sup; this part is soluble protein) and the inclusion body precipitate (Pellet, Pel). The soluble protein in the supernatant was purified using a streptavidin chromatography column and a nickel column (Ni), respectively. The specific method is to pass 5 mL of supernatant through 200 μL of the chromatography column stationary phase, wash the chromatography column with 15 mL of Buffer A, and draw 20 μL of the stationary phase Beads and add the electrophoresis loading buffer for SDS-PAGE blue staining detection. The results show that the target protein is bound to the chromatography column stationary phase (Beads lane). After the stationary phase was digested with 3C protease in the column (200 μL of 3C protease digestion solution containing 1 international unit was added to the column phase and digested at 4°C for 16 hours), it was eluted with 1 mL of PBS. The eluate was subjected to electrophoresis and staining detection, and the blue-stained band of Galectin-8 (green arrow) with the label removed appeared in the Elution lane ( Fig.15). Using this system, 0.4 mg of purified protein can be obtained per liter of LB medium host bacteria, and its yield is equivalent to that of a nickel column (see the rightmost lane). It can be seen that the soluble protein induced by the recombinant vector provided by the present invention can be purified using a Streptavidin chromatography column under non-denaturing conditions. The results of the above examples show that the P67 tag that can be recognized by the host cell and produce biotinylated modification can be used to purify soluble and insoluble recombinant target proteins using a traditional streptavidin chromatography column.
[0168] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A reversible label P67, characterized in that: Including at least one of the following: a PCC tag, a PC tag, an ACCA tag, and a mutant of the PCC tag, PC tag or ACCA tag; The amino acid sequences of the PCC tag, PC tag and ACCA tag are shown in SEQ ID NO:1 to SEQ ID NO:3; the mutant of the PCC tag, PC tag or ACCA tag is that the 33rd lysine is mutated to glutamic acid or proline based on the amino acid sequence of the PCC tag, PC tag or ACCA tag.
2. A gene encoding the renaturing tag P67 according to claim 1, characterized in that: The nucleotide sequence of the encoding gene is at least one of the following shown in SEQ ID NO:4 to SEQ ID NO:
8.
3. A prokaryotic protein expression tool plasmid, characterized in that: It comprises a nucleic acid molecule expressing the renaturing tag P67 according to claim 1 or a coding gene according to claim 2.
4. The prokaryotic protein expression tool plasmid according to claim 3, characterized in that: The pET41a vector is used as a backbone vector, wherein the GST tag is replaced by the coding gene.
5. The prokaryotic recombination tool plasmid according to claim 4, characterized in that: It also includes a HRV-3C protease recognition cleavage site or a TEV protease recognition site.
6. A prokaryotic recombinant vector for expressing a target protein, characterized in that: The prokaryotic protein expression tool plasmid described in any one of claims 3 to 5 is used as a backbone vector, and further comprises a target protein gene; The cloning site of the target protein gene is between the NcoI and XhoI multiple cloning sites or between the BamHI and XhoI multiple cloning sites.
7. A fusion protein, characterized in that The protein is obtained by fusion expression of the refolding-aiding tag P67 described in claim 1 and the target protein.
8. A fusion gene, characterized in that: The coding gene and the target gene described in claim 2 are connected in series.
9. Use of the renaturation-aiding tag P67 according to claim 1, the coding gene according to claim 2, the prokaryotic protein expression tool plasmid according to any one of claims 3 to 5, the prokaryotic recombinant vector according to claim 6, the fusion protein according to claim 7 or the fusion gene according to claim 8 in inclusion body purification.
10. A method for purifying inclusion body protein, characterized in that: The following steps are involved: Cloning the target protein gene into the prokaryotic protein expression tool plasmid described in any one of claims 3 to 5 to obtain a recombinant vector; Transforming the recombinant vector into a prokaryotic expression system competent state, culturing and inducing the target protein, and isolating the inclusion body protein; Denaturing and dissolving the inclusion body protein to obtain denatured and dissolved inclusion body protein; The denatured and dissolved inclusion body protein is dialyzed and renatured to obtain a purified renatured protein.
Citation Information
Patent Citations
Biomolecular labelling using multifunctional biotin analogues
CN102439014A
Tag protein as well as coding gene, recombinant vector and application thereof
CN113388009A
